Genetic test could shorten hospital stays for fungal infection patients

NCT ID NCT03554239

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study explores whether a genetic test (CYP2C19) can help doctors choose the right dose of the antifungal drug voriconazole more quickly. Patients starting voriconazole for an infection will give a blood sample for genotyping. The goal is to see if this personalized dosing reduces the number of days spent in the hospital compared to standard monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

genetic test (CYP2C19 genotyping)

What this could lead to

If successful, this approach could help doctors personalize antifungal dosing, potentially shortening hospital stays and reducing side effects.

What could go wrong

This is a small, early-stage study focused on feasibility. Genetic testing may not significantly change outcomes, and results may not apply to broader populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fungal infectious disease Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.